In: Neurochemical Research, 2015, vol. 40, no. 12, p. 2639-2646
|
In: Plos pathogens, 2018, vol. 14, no. 10, p. e1007335
Antibodies to the prion protein, PrP, represent a promising therapeutic approach against prion diseases but the neurotoxicity of certain anti-PrP antibodies has caused concern. Here we describe scPOM-bi, a bispecific antibody designed to function as a molecular prion tweezer. scPOM-bi combines the complementarity-determining regions of the neurotoxic antibody POM1 and the neuroprotective...
|
In: Acta Neuropathologica, 2014, vol. 128, no. 2, p. 231-246
|
In: European Journal of Pediatrics, 2014, vol. 173, no. 12, p. 1691-1694
|
In: The journal of biological chemistry, 2015, vol. 290, no. 39, p. 23631-23645
Although the accumulation of a misfolded and protease-resistant form of the prion protein (PrP) is a key event in Prion pathogenesis, the cellular factors involved in its folding and quality control are poorly understood. PrP is a glycosylated and disulfide-bonded protein synthesized at the endoplasmic reticulum (ER). The ER foldase ERp57 (also known as Grp58) is highly expressed in the brain...
|
In: Journal of Neurology, 2008, vol. 255, no. 1, p. 133-134
|
In: Journal of Neurology, 2008, vol. 255, no. 1, p. 77-88
|
In: Acta Neuropathologica, 2004, vol. 108, no. 1, p. 65-68
|
In: European Radiology, 2011, vol. 21, no. 4, p. 857-862
|
In: Journal of Neurology, 2007, vol. 254, no. 2, p. 146-153
|